BIIB vs INTS
Biogen Inc (BIIB) versus Intensity Therapeutics, Inc. Common stock (INTS) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
INTS does not have a complete income-statement cache yet.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. INTS currently screens at market cap $7.7M.
Not investment advice. Open the BIIB and INTS stock pages for the full models.
Not investment advice.